



Selective Chelators for Metals on Cells and Cancer Chemotherapy

Guest Editor:

Dr. Luís M. T. Frija

Centro de Química Estrutural,
Instituto Superior Técnico -
Universidade de Lisboa, Lisbon,
Portugal

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues,

Cancer research continues to be one of the leading banners in medicine and the pharmaceutical sciences. Since this is a topic of great interest to society, the fields of knowledge that act directly in the fight against this disease are numerous and are transversal to different central sciences, such as chemistry, physics or biology. In this context, there are several types of treatments applied for cancer eradication, with chemotherapy procedures leading the way. Besides, the designation of cancer chemotherapy by yourself is quite broad, comprising a large number of medicines and medical practices.

One of the approaches used to combat cancer cell proliferation is based on the application of molecules with chelating / ligand properties, selective for different metals in cell media. In this context, the present special Issue aims to combine a collection of original and review articles comprising basic science, preclinical and clinical discoveries that embrace metal-chelating compounds for cancer chemotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com